Biotech · Private company · San Diego, CA, US
Origami Therapeutics, Inc.
Track this companyFree. Adds Origami Therapeutics, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials0None registered
Pipeline programs0None found yet
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
NIH awards2
- Uncovering the molecular target(s) of ORI-113, a potential brain-penetrant small molecule therapeutic for Huntington's disease.Fiscal year 2025 · $500KNIH RePORTER 1R43NS145855-01 · fetched Nov 12, 2026
- Characterization of small molecules that lower mutant huntingtin protein as potential therapeutics for Huntington’s diseaseFiscal year 2024 · $107.1KNIH RePORTER 5R43NS127716-02 · fetched Nov 12, 2026